Easing restrictions in the UK
The United Kingdom has eased restrictions on Epidyolex, placing it on the lowest level of control. The cannabis-based medicine is moving from Schedule 2 to a Schedule 5 under the Misuse of Drugs Regulations 2001.
This move will take effect immediately throughout the United Kingdom, with Northern Ireland enacting separate legislation.
“The decision to move Epidyolex to a low level of control is an important one for patients, their families, health-care professionals, pharmacists and the NHS as a whole – reducing costs and ensuring the medicine can be dispensed more easily,” Chris Tovey, GW Pharma’s COO, stated in a press release.
Epidyolex is an oral solution containing highly purified cannabidiol or CBD. It received approval in 2019 for treatment of seizure relating to Dravet syndrome or Lennox-Gastaut syndrome (LGS).
It is available in the U.S. under the name Epidiolex. In 2018, it was removed entirely from the controlled substance list in the United States.
Low risk, big reward
In making their decision, the advisory council cited the “low risk of abuse potential, low-risk dependency and low risk of diversion.”
GW Pharma’s medicines are now free from all controlled drug requirements. This means that patients will have greater freedom and flexibility on their medications and repeat prescriptions.
The pharmaceutical company are now in a strong stock position with all analysts rating the stock a buy.
RELATED: FSD Pharma swaps cannabis for COVID